Comparison of 6-18F-Fluoro-l-DOPA, 18F-2-deoxy-d- glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease

Mio Kitano, Corina Millo, Reza Rahbari, Peter Herscovitch, Krisana Gesuwan, Richard C. Webb, Aradhana M. Venkatesan, Giao Q. Phan, Marybeth S. Hughes, Steven K. Libutti, Naris Nilubol, William M. Linehan, Electron Kebebew

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Introduction: There are limited data on the utility of 6- 18F-fluoro-l-3,4-dihydroxyphenylalanine (18F-DOPA) and 18F-2-deoxy-d-glucose (18F-FDG) in the workup of patients with pancreatic neuroendocrine tumors (PNETs). The aim of our study was to determine the accuracy of 18F-DOPA and 18F-FDG to detect PNETs in patients with von Hippel-Lindau disease (vHL). Methods: We studied prospectively 69 patients with a diagnosis of vHL and pancreatic lesion(s) using computed tomography (CT), magnetic resonance imaging (MRI), 18F-FDG, and 18F-DOPA. Clinical, genetic, and laboratory characteristics were analyzed to determine association with imaging study results. Results: In sum, 40 patients underwent evaluation by all 4 modalities; 98 PNETs and 55 PNETs were identified on CT and MRI, respectively. Only 11 of the 98 lesions (11%) were positive on 18F-DOPA and 45 of the 98 (46%) lesions were positive on 18F-FDG. There were 13 18F-DOPA and 26 18F-FDG avid extrapancreatic lesions. One patient underwent resection of an 18F-DOPA avid extrapancreatic lesion in the lung, with pathology demonstrating a NET. There was no association between 18F-DOPA and 18F-FDG avidity and tumor size, age, gender, vHL mutation, or serum chromogranin A level. Conclusion: 18F-FDG and MRI may be adjuncts to CT in identifying PNETs and metastatic disease. 18F-DOPA has limited value in identifying PNETs in patients with vHL, but may be useful for identifying extrapancreatic NET lesions.

Original languageEnglish (US)
Pages (from-to)1122-1128
Number of pages7
JournalSurgery
Volume150
Issue number6
DOIs
StatePublished - Dec 2011

Fingerprint

von Hippel-Lindau Disease
Dihydroxyphenylalanine
Pancreatic Neoplasms
Neuroendocrine Tumors
Tomography
Magnetic Resonance Imaging
Glucose
Chromogranin A
Pathology
Lung
Mutation

ASJC Scopus subject areas

  • Surgery

Cite this

Comparison of 6-18F-Fluoro-l-DOPA, 18F-2-deoxy-d- glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. / Kitano, Mio; Millo, Corina; Rahbari, Reza; Herscovitch, Peter; Gesuwan, Krisana; Webb, Richard C.; Venkatesan, Aradhana M.; Phan, Giao Q.; Hughes, Marybeth S.; Libutti, Steven K.; Nilubol, Naris; Linehan, William M.; Kebebew, Electron.

In: Surgery, Vol. 150, No. 6, 12.2011, p. 1122-1128.

Research output: Contribution to journalArticle

Kitano, M, Millo, C, Rahbari, R, Herscovitch, P, Gesuwan, K, Webb, RC, Venkatesan, AM, Phan, GQ, Hughes, MS, Libutti, SK, Nilubol, N, Linehan, WM & Kebebew, E 2011, 'Comparison of 6-18F-Fluoro-l-DOPA, 18F-2-deoxy-d- glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease', Surgery, vol. 150, no. 6, pp. 1122-1128. https://doi.org/10.1016/j.surg.2011.09.048
Kitano, Mio ; Millo, Corina ; Rahbari, Reza ; Herscovitch, Peter ; Gesuwan, Krisana ; Webb, Richard C. ; Venkatesan, Aradhana M. ; Phan, Giao Q. ; Hughes, Marybeth S. ; Libutti, Steven K. ; Nilubol, Naris ; Linehan, William M. ; Kebebew, Electron. / Comparison of 6-18F-Fluoro-l-DOPA, 18F-2-deoxy-d- glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease. In: Surgery. 2011 ; Vol. 150, No. 6. pp. 1122-1128.
@article{7984111b827b4a729d5726c3bba67928,
title = "Comparison of 6-18F-Fluoro-l-DOPA, 18F-2-deoxy-d- glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease",
abstract = "Introduction: There are limited data on the utility of 6- 18F-fluoro-l-3,4-dihydroxyphenylalanine (18F-DOPA) and 18F-2-deoxy-d-glucose (18F-FDG) in the workup of patients with pancreatic neuroendocrine tumors (PNETs). The aim of our study was to determine the accuracy of 18F-DOPA and 18F-FDG to detect PNETs in patients with von Hippel-Lindau disease (vHL). Methods: We studied prospectively 69 patients with a diagnosis of vHL and pancreatic lesion(s) using computed tomography (CT), magnetic resonance imaging (MRI), 18F-FDG, and 18F-DOPA. Clinical, genetic, and laboratory characteristics were analyzed to determine association with imaging study results. Results: In sum, 40 patients underwent evaluation by all 4 modalities; 98 PNETs and 55 PNETs were identified on CT and MRI, respectively. Only 11 of the 98 lesions (11{\%}) were positive on 18F-DOPA and 45 of the 98 (46{\%}) lesions were positive on 18F-FDG. There were 13 18F-DOPA and 26 18F-FDG avid extrapancreatic lesions. One patient underwent resection of an 18F-DOPA avid extrapancreatic lesion in the lung, with pathology demonstrating a NET. There was no association between 18F-DOPA and 18F-FDG avidity and tumor size, age, gender, vHL mutation, or serum chromogranin A level. Conclusion: 18F-FDG and MRI may be adjuncts to CT in identifying PNETs and metastatic disease. 18F-DOPA has limited value in identifying PNETs in patients with vHL, but may be useful for identifying extrapancreatic NET lesions.",
author = "Mio Kitano and Corina Millo and Reza Rahbari and Peter Herscovitch and Krisana Gesuwan and Webb, {Richard C.} and Venkatesan, {Aradhana M.} and Phan, {Giao Q.} and Hughes, {Marybeth S.} and Libutti, {Steven K.} and Naris Nilubol and Linehan, {William M.} and Electron Kebebew",
year = "2011",
month = "12",
doi = "10.1016/j.surg.2011.09.048",
language = "English (US)",
volume = "150",
pages = "1122--1128",
journal = "Surgery (United States)",
issn = "0039-6060",
publisher = "Mosby Inc.",
number = "6",

}

TY - JOUR

T1 - Comparison of 6-18F-Fluoro-l-DOPA, 18F-2-deoxy-d- glucose, CT, and MRI in patients with pancreatic neuroendocrine neoplasms with von Hippel-Lindau disease

AU - Kitano, Mio

AU - Millo, Corina

AU - Rahbari, Reza

AU - Herscovitch, Peter

AU - Gesuwan, Krisana

AU - Webb, Richard C.

AU - Venkatesan, Aradhana M.

AU - Phan, Giao Q.

AU - Hughes, Marybeth S.

AU - Libutti, Steven K.

AU - Nilubol, Naris

AU - Linehan, William M.

AU - Kebebew, Electron

PY - 2011/12

Y1 - 2011/12

N2 - Introduction: There are limited data on the utility of 6- 18F-fluoro-l-3,4-dihydroxyphenylalanine (18F-DOPA) and 18F-2-deoxy-d-glucose (18F-FDG) in the workup of patients with pancreatic neuroendocrine tumors (PNETs). The aim of our study was to determine the accuracy of 18F-DOPA and 18F-FDG to detect PNETs in patients with von Hippel-Lindau disease (vHL). Methods: We studied prospectively 69 patients with a diagnosis of vHL and pancreatic lesion(s) using computed tomography (CT), magnetic resonance imaging (MRI), 18F-FDG, and 18F-DOPA. Clinical, genetic, and laboratory characteristics were analyzed to determine association with imaging study results. Results: In sum, 40 patients underwent evaluation by all 4 modalities; 98 PNETs and 55 PNETs were identified on CT and MRI, respectively. Only 11 of the 98 lesions (11%) were positive on 18F-DOPA and 45 of the 98 (46%) lesions were positive on 18F-FDG. There were 13 18F-DOPA and 26 18F-FDG avid extrapancreatic lesions. One patient underwent resection of an 18F-DOPA avid extrapancreatic lesion in the lung, with pathology demonstrating a NET. There was no association between 18F-DOPA and 18F-FDG avidity and tumor size, age, gender, vHL mutation, or serum chromogranin A level. Conclusion: 18F-FDG and MRI may be adjuncts to CT in identifying PNETs and metastatic disease. 18F-DOPA has limited value in identifying PNETs in patients with vHL, but may be useful for identifying extrapancreatic NET lesions.

AB - Introduction: There are limited data on the utility of 6- 18F-fluoro-l-3,4-dihydroxyphenylalanine (18F-DOPA) and 18F-2-deoxy-d-glucose (18F-FDG) in the workup of patients with pancreatic neuroendocrine tumors (PNETs). The aim of our study was to determine the accuracy of 18F-DOPA and 18F-FDG to detect PNETs in patients with von Hippel-Lindau disease (vHL). Methods: We studied prospectively 69 patients with a diagnosis of vHL and pancreatic lesion(s) using computed tomography (CT), magnetic resonance imaging (MRI), 18F-FDG, and 18F-DOPA. Clinical, genetic, and laboratory characteristics were analyzed to determine association with imaging study results. Results: In sum, 40 patients underwent evaluation by all 4 modalities; 98 PNETs and 55 PNETs were identified on CT and MRI, respectively. Only 11 of the 98 lesions (11%) were positive on 18F-DOPA and 45 of the 98 (46%) lesions were positive on 18F-FDG. There were 13 18F-DOPA and 26 18F-FDG avid extrapancreatic lesions. One patient underwent resection of an 18F-DOPA avid extrapancreatic lesion in the lung, with pathology demonstrating a NET. There was no association between 18F-DOPA and 18F-FDG avidity and tumor size, age, gender, vHL mutation, or serum chromogranin A level. Conclusion: 18F-FDG and MRI may be adjuncts to CT in identifying PNETs and metastatic disease. 18F-DOPA has limited value in identifying PNETs in patients with vHL, but may be useful for identifying extrapancreatic NET lesions.

UR - http://www.scopus.com/inward/record.url?scp=82755195101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82755195101&partnerID=8YFLogxK

U2 - 10.1016/j.surg.2011.09.048

DO - 10.1016/j.surg.2011.09.048

M3 - Article

C2 - 22136831

AN - SCOPUS:82755195101

VL - 150

SP - 1122

EP - 1128

JO - Surgery (United States)

JF - Surgery (United States)

SN - 0039-6060

IS - 6

ER -